<?xml version="1.0" encoding="UTF-8"?>
<abstract id="15860827">
  <title>
    <s id="0" section="title">
      Randomised controlled trial of
      <group id="0">
        <short>calcium  and  supplementation  with  cholecalciferol</short>
        (  vitamin  D3  )
      </group>
      for
      <outcome id="0">prevention  of  fractures</outcome>
      in primary care .
    </s>
  </title>
  <annotated>
    <s id="1" section="objective">
      To assess whether
      <group id="0">
        <short>supplementation  with  calcium  and  cholecaliferol</short>
        (  vitamin  D3  )
      </group>
      reduces the
      <outcome id="0">risk  of  fracture</outcome>
      in women with 1 or more risk factors for fracture of the hip .
    </s>
    <s id="4" section="participants">
      <ps>3314</ps>
      women aged 70 and over with 1 or more risk factors for hip fracture : any previous fracture , low body weight ( &lt; 58 kg ) , smoker , family history of hip fracture , or fair or poor self reported health .
    </s>
    <s id="5" section="intervention">
      <group id="0">
        <short>Daily  oral  supplementation</short>
        using  1000  mg  calcium  with  800  IU  cholecaliferol  and  information  leaflet  on  dietary  calcium  intake  and  prevention  of  falls
      </group>
      , or
      <group id="0">leaflet  only</group>
      (
      <group id="1">control  group</group>
      ) .
    </s>
    <s id="7" section="results">
      69 % of the women who completed the follow - up questionnaire at
      <time id="0">24  months</time>
      were
      <outcome id="1">still  taking  supplements</outcome>
      ( 55 % with inclusion of randomised participants known to be alive ) .
    </s>
    <s id="8" section="results">
      After a median follow - up of
      <time id="1">25  months</time>
      ( range 18 to 42 months ) ,
      <outcome id="0">clinical  fracture  rates</outcome>
      were lower than expected in both groups but did not significantly differ for
      <outcome id="0">all  clinical  fractures</outcome>
      ( odds ratio for fracture in
      <group id="0">supplemented  group</group>
      1.01 , 95 % confidence interval 0.71 to 1.43 ) .
    </s>
    <s id="10" section="results">
      The odds of a woman having a
      <outcome id="2">fall</outcome>
      at
      <time id="2">6</time>
      and
      <time id="3">12  months</time>
      was 0.99 and 0.98 , respectively .
    </s>
    <s id="12" section="conclusion">
      We found no evidence that
      <group id="0">calcium  and  vitamin  D  supplementation</group>
      reduces the
      <outcome id="0">risk  of  clinical  fractures</outcome>
      in women with 1 or more risk factors for hip fracture .
    </s>
  </annotated>
  <fulltext>Randomised controlled trial of calcium and supplementation with cholecalciferol ( vitamin D3 ) for prevention of fractures in primary care . To assess whether supplementation with calcium and cholecaliferol ( vitamin D3 ) reduces the risk of fracture in women with 1 or more risk factors for fracture of the hip . Pragmatic open randomised controlled trial . Practice nurse led clinics in primary care . 3314 women aged 70 and over with 1 or more risk factors for hip fracture : any previous fracture , low body weight ( &lt; 58 kg ) , smoker , family history of hip fracture , or fair or poor self reported health . Daily oral supplementation using 1000 mg calcium with 800 IU cholecaliferol and information leaflet on dietary calcium intake and prevention of falls , or leaflet only ( control group ) . Primary outcome measure was all clinical fractures and secondary outcome measures were adherence to treatment , falls , and quality of life ( measured with the SF-12 ) . 69 % of the women who completed the follow - up questionnaire at 24 months were still taking supplements ( 55 % with inclusion of randomised participants known to be alive ) . After a median follow - up of 25 months ( range 18 to 42 months ) , clinical fracture rates were lower than expected in both groups but did not significantly differ for all clinical fractures ( odds ratio for fracture in supplemented group 1.01 , 95 % confidence interval 0.71 to 1.43 ) . The odds ratio for hip fracture was 0.75 ( 0.31 to 1.78 ) . The odds of a woman having a fall at 6 and 12 months was 0.99 and 0.98 , respectively . Quality of life did not significantly differ between the groups . We found no evidence that calcium and vitamin D supplementation reduces the risk of clinical fractures in women with 1 or more risk factors for hip fracture . Registration ISRCTN26118436 , controlled trials registry .</fulltext>
  <ignored>
    <s id="2" section="design">Pragmatic open randomised controlled trial .</s>
    <s id="3" section="setting">Practice nurse led clinics in primary care .</s>
    <s id="6" section="main_outcome_measures">
      Primary outcome measure was
      <outcome id="0">all  clinical  fractures</outcome>
      and secondary outcome measures were
      <outcome id="1">adherence  to  treatment</outcome>
      ,
      <outcome id="2">falls</outcome>
      , and
      <outcome id="3">quality  of  life</outcome>
      ( measured with the SF-12 ) .
    </s>
    <s id="9" section="results">
      The odds ratio for
      <outcome id="0">hip  fracture</outcome>
      was 0.75 ( 0.31 to 1.78 ) .
    </s>
    <s id="11" section="results">
      <outcome id="3">Quality  of  life</outcome>
      did not significantly differ between the groups .
    </s>
    <s id="13" section="conclusion">Registration ISRCTN26118436 , controlled trials registry .</s>
  </ignored>
</abstract>

